Selenium (Se) and the risk of breast, ovarian and prostate cancers by Katarzyna Jaworska et al.
MEETING ABSTRACT Open Access
Selenium (Se) and the risk of breast, ovarian and
prostate cancers
Katarzyna Jaworska*, Anna Jakubowska, Katarzyna Durda, Tomasz Huzarski, Pablo Serrano-Fernandez,
Grzegorz Sukiennicki, Magdalena Muszyńska, Tomasz Byrski, Jacek Gronwald, Satish Gupta, K Kaczmarek,
Jan Lubiński
From Annual Conference on Hereditary Cancers 2011
Szczecin, Poland. 17-18 November 2011
Aim of the study
The aim of the study was determination of serum Se
concentration and identification of genetic variations in
genes related to metabolism of selenium as markers of
cancer risks for carriers of BRCA1 gene mutation and
individuals with susceptibility to other common unse-
lected cancers (breast, ovarian, prostate).
Material and methods
Eight genotypes of 4 most common SNPs localised in
GPX1, GPX4, TXNRD2 and SEP15 were selected. Geno-
typing was performed in 93 affected and 186 unaffected
matched BRCA1 carriers as well as on pairs matched
1:1 consisting of 108 breast, 50 ovarian and 105 prostate
consecutive cancer patients and healthy controls.
The following techniques for laboratory analyses have
been applied: a) sequencing on ABI310, b) SimpleProbe
or TaqMan analysis (a melting-curve genotyping with
fluorescence-labeled probes based on the LightCycler
480 System (Roche Applied Science), c) determination
of selenium concentration in plasma using atomic
absorption spectrometer AAnalyst600 (Perkin Elmer).
Results
In none of studied groups statistically significant differ-
ences on cancer risk could be found when serum sele-
nium concentration was assessed as a single factor.
However, when selenium level data were combined with
some selenoprotein genotypes some strong associations
with cancer risk have been identified.
BRCA1
The strongest association was found for carriers of
SEP15 nGG genotype (Tab.1). Additionally, significantly
lower risk of cancers were found for GPX1 CC (for Se
level >80µg/l, ~ 6 times) and GPX4 CC (for Se level
>100µg/l, ~10 times).
Unselected breast cancers
The strongest association was found for carriers of
SEP15 nGG genotype (Tab.1).
Significantly lower risk of cancer was found also for
TXNRD2 GG (for Se level 60 - 80µg/l, ~ 4 times) and
GPX1 nCC/TXNRD2 nGG/SEP15 GG (for Se level
<55µg/l, ~10 times).
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Table 1 Correlation between cancer risk and serum
selenium concentration in carriers of SEP15 nGG
genotype.
BRCA1 gene mutation carriers
Genotype Se No Chi2teste
Cancers Controls p OR CI
Sep15nGG <56µg/l 16 6 0.0005 43 2.2-861
>95µg/l 0 8
Unselected breast cancers carriers
Genotype Se No Chi2teste
Cancers Controls p OR CI
Sep15nGG <56µg/l 7 5 0.009 18.2 1.8-188
>95µg/l 1 13
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Unselected ovarian cancers
Results were not statistically significant however tenden-
cies similar to those found in BRCA1 carriers and unse-
lected breast cancer were observed.
Unselected prostate cancers
For four genotypes: GPX1 CC, GPX4 nCC, TXNRD2
GG and SEP15 nGG lower risk (~3 times) was found
for selenium level ~90µg/l.
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